Pelareorep Plus Paclitaxel: A New Hope in Cancer Treatment for HR+/HER2- Breast Cancer

Wednesday, 18 September 2024, 17:00

Cancer research is making significant strides with the success of pelareorep combined with paclitaxel in oncology. This breakthrough offers encouraging results for patients battling hormone receptor-positive/HER2-negative breast cancer. The phase 2 BRACELET-1 study highlights extended overall survival rates that could reshape treatment protocols. Following the study, many patients remain hopeful with improvements in their condition due to innovative therapies.
Targetedonc
Pelareorep Plus Paclitaxel: A New Hope in Cancer Treatment for HR+/HER2- Breast Cancer

Significant Findings in Cancer Treatment

The median overall survival (OS) was not reached with the combination of the oncolytic viral therapy pelareorep (Reolysin) plus paclitaxel for the treatment of patients with hormone receptor (HR)-positive/HER2-negative breast cancer, according to positive results from the phase 2 BRACELET-1 study (NCT04215146).

Study Details and Efficacy

Final efficacy data from the randomized BRACELET-1 trial were collected and analyzed 2 years following the enrollment of the last patient, as specified by the protocol. In the pelareorep/paclitaxel arm, more than half of the patients remained alive at the end of the study compared with a median OS of 18.2 months in the paclitaxel monotherapy arm (HR, 0.48).

Projecting Future Outcomes

If the study follow-up had continued beyond the 2-year mark, and patients had only lived until their next planned visit in 4 months, the projected median OS in the pelareorep plus paclitaxel arm would have been 32.1 months.


Disclaimer: The information provided on this site is for informational purposes only and is not intended as medical advice. We are not responsible for any actions taken based on the content of this site. Always consult a qualified healthcare provider for medical advice, diagnosis, and treatment. We source our news from reputable sources and provide links to the original articles. We do not endorse or assume responsibility for the accuracy of the information contained in external sources.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Subscribe to our newsletter for the latest and most reliable health updates. Stay informed and enhance your wellness knowledge effortlessly.

Subscribe